Effectiveness and Persistence of Liraglutide Treatment Among Patients with Type 2 Diabetes Treated in Primary Care and Specialist Settings: A Subgroup Analysis from the EVIDENCE Study, a Prospective, 2-Year Follow-up, Observational, Post-Marketing Study.

Martinez L, Penfornis A, Gautier JF, Eschwège E, Charpentier G, Bouzidi A, Gourdy P

Advances in therapy30 Jan 2017Cited by 10 (Europe PMC)

PMID28138803PMCIDPMC5350193DOI10.1007/s12325-017-0476-0PepBankPUB-28138803

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes treated in specialist care, 21.2% still used liraglutide and kept HbA1c below 7.0% after 2 years.
In plain wordsIn adults with type 2 diabetes treated by specialists, 21.2% still used liraglutide and kept HbA1c below 7.0% after 2 years.
Peptide
Liraglutide
Outcome
Not applicablePersistence on liraglutide with HbA1c below 7.0% at 2 years, specialist cohort
Study
n = 1,398
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Patients on liraglutide with HbA1c <7.0%
21.2%
specialist-treated
Source sentences
Summary
After 2 years of follow-up, 477 out of 1209 (39.0%) of PCP and 297 out of 1398 (21.2%) of specialist-treated patients still used liraglutide and maintained the glycated hemoglobin (HbA_1c) target of <7.0%.
2 context sentences(design, population, supporting numbers)
Summary · context
EVIDENCE is a prospective, observational study of 3152 adults with T2D recently starting or about to start liraglutide treatment in France.
Summary · context
We followed patients in the PCP and specialist settings for 2 years to evaluate the effectiveness of liraglutide in glycemic control and body weight reduction.
Report a problemFND-2813880302
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes treated in primary care, 39.0% still used liraglutide and kept HbA1c below 7.0% after 2 years.
In plain wordsIn adults with type 2 diabetes treated by primary care doctors, 39.0% still used liraglutide and kept HbA1c below 7.0% after 2 years.
Peptide
Liraglutide
Outcome
Not applicablePersistence on liraglutide with HbA1c below 7.0% at 2 years, PCP cohort
Study
n = 1,209
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Patients on liraglutide with HbA1c <7.0%
39%
PCP-treated
Source sentences
Summary
After 2 years of follow-up, 477 out of 1209 (39.0%) of PCP and 297 out of 1398 (21.2%) of specialist-treated patients still used liraglutide and maintained the glycated hemoglobin (HbA_1c) target of <7.0%.
2 context sentences(design, population, supporting numbers)
Summary · context
EVIDENCE is a prospective, observational study of 3152 adults with T2D recently starting or about to start liraglutide treatment in France.
Summary · context
We followed patients in the PCP and specialist settings for 2 years to evaluate the effectiveness of liraglutide in glycemic control and body weight reduction.
Report a problemFND-2813880301
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, liraglutide reduced mean HbA1c from baseline in both primary care (-1.22%) and specialist (-0.8%) cohorts.
In plain wordsIn adults with type 2 diabetes on liraglutide, HbA1c fell by 1.22% in primary care and 0.8% in specialist care.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change from baseline
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
HbA1c change
−1.22%
PCP-treated
HbA1c change
−0.8%
specialist-treated
Source sentences
Summary
Significant reductions from baseline were observed in both PCP- and specialist-treated cohorts in mean HbA_1c (-1.22% and -0.8%, respectively), fasting plasma glucose (FPG) concentration (-39 and -23 mg/dL), body weight (-4.4 and -3.8 kg), and body mass index (BMI) (-1.5 and -1.4 kg/m…
2 context sentences(design, population, supporting numbers)
Summary · context
EVIDENCE is a prospective, observational study of 3152 adults with T2D recently starting or about to start liraglutide treatment in France.
Summary · context
We followed patients in the PCP and specialist settings for 2 years to evaluate the effectiveness of liraglutide in glycemic control and body weight reduction.
Report a problemFND-2813880303
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, liraglutide reduced fasting plasma glucose from baseline in primary care (-39 mg/dL) and specialist (-23 mg/dL) cohorts.
In plain wordsIn adults with type 2 diabetes on liraglutide, fasting glucose fell by 39 mg/dL in primary care and 23 mg/dL in specialist care.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose change from baseline
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Fasting plasma glucose change
−39 mg/dL
PCP-treated
Fasting plasma glucose change
−23 mg/dL
specialist-treated
Source sentences
Summary
Significant reductions from baseline were observed in both PCP- and specialist-treated cohorts in mean HbA_1c (-1.22% and -0.8%, respectively), fasting plasma glucose (FPG) concentration (-39 and -23 mg/dL), body weight (-4.4 and -3.8 kg), and body mass index (BMI) (-1.5 and -1.4 kg/m…
2 context sentences(design, population, supporting numbers)
Summary · context
EVIDENCE is a prospective, observational study of 3152 adults with T2D recently starting or about to start liraglutide treatment in France.
Summary · context
We followed patients in the PCP and specialist settings for 2 years to evaluate the effectiveness of liraglutide in glycemic control and body weight reduction.
Report a problemFND-2813880304
05HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, liraglutide reduced body weight from baseline in primary care (-4.4 kg) and specialist (-3.8 kg) cohorts.
In plain wordsIn adults with type 2 diabetes on liraglutide, weight fell by 4.4 kg in primary care and 3.8 kg in specialist care.
Peptide
Liraglutide
Outcome
DecreaseBody weight change from baseline
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Body weight change
−4.4 kg
PCP-treated
Body weight change
−3.8 kg
specialist-treated
Source sentences
Summary
Significant reductions from baseline were observed in both PCP- and specialist-treated cohorts in mean HbA_1c (-1.22% and -0.8%, respectively), fasting plasma glucose (FPG) concentration (-39 and -23 mg/dL), body weight (-4.4 and -3.8 kg), and body mass index (BMI) (-1.5 and -1.4 kg/m…
2 context sentences(design, population, supporting numbers)
Summary · context
EVIDENCE is a prospective, observational study of 3152 adults with T2D recently starting or about to start liraglutide treatment in France.
Summary · context
We followed patients in the PCP and specialist settings for 2 years to evaluate the effectiveness of liraglutide in glycemic control and body weight reduction.
Report a problemFND-2813880305
06HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, liraglutide reduced BMI from baseline in primary care (-1.5 kg/m2) and specialist (-1.4 kg/m2) cohorts.
In plain wordsIn adults with type 2 diabetes, BMI fell in both groups of liraglutide-treated patients, by 1.5 in primary care and 1.4 in specialist care.
Peptide
Liraglutide
Outcome
DecreaseBody mass index change from baseline
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
BMI change
−1.5 kg/m2
PCP-treated
BMI change
−1.4 kg/m2
specialist-treated
Source sentences
Summary
Significant reductions from baseline were observed in both PCP- and specialist-treated cohorts in mean HbA_1c (-1.22% and -0.8%, respectively), fasting plasma glucose (FPG) concentration (-39 and -23 mg/dL), body weight (-4.4 and -3.8 kg), and body mass index (BMI) (-1.5 and -1.4 kg/m…
2 context sentences(design, population, supporting numbers)
Summary · context
EVIDENCE is a prospective, observational study of 3152 adults with T2D recently starting or about to start liraglutide treatment in France.
Summary · context
We followed patients in the PCP and specialist settings for 2 years to evaluate the effectiveness of liraglutide in glycemic control and body weight reduction.
Report a problemFND-2813880306
07HumanObservational studyEfficacy outcome
In adults with type 2 diabetes treated with liraglutide, the HbA1c reduction was significantly greater in primary care than in specialist care.
In plain wordsIn adults with type 2 diabetes on liraglutide, HbA1c fell more in patients treated in primary care than in those treated by specialists.
Peptide
Liraglutide
Outcome
Not applicableHbA1c reduction, primary care versus specialist care
Study
n: not reported in source
Comparator
Specialist-treated patients
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Reductions in HbA_1c and FPG were significantly greater among PCP- compared with specialist-treated patients, p < 0.0001 for both.
2 context sentences(design, population, supporting numbers)
Summary · context
EVIDENCE is a prospective, observational study of 3152 adults with T2D recently starting or about to start liraglutide treatment in France.
Summary · context
We followed patients in the PCP and specialist settings for 2 years to evaluate the effectiveness of liraglutide in glycemic control and body weight reduction.
Report a problemFND-2813880307
08HumanObservational studyEfficacy outcome
In adults with type 2 diabetes treated with liraglutide, the fasting plasma glucose reduction was significantly greater in primary care than in specialist care.
In plain wordsIn adults with type 2 diabetes on liraglutide, fasting glucose fell more in patients treated in primary care than in those treated by specialists.
Peptide
Liraglutide
Outcome
Not applicableFasting plasma glucose reduction, primary care versus specialist care
Study
n: not reported in source
Comparator
Specialist-treated patients
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Reductions in HbA_1c and FPG were significantly greater among PCP- compared with specialist-treated patients, p < 0.0001 for both.
2 context sentences(design, population, supporting numbers)
Summary · context
EVIDENCE is a prospective, observational study of 3152 adults with T2D recently starting or about to start liraglutide treatment in France.
Summary · context
We followed patients in the PCP and specialist settings for 2 years to evaluate the effectiveness of liraglutide in glycemic control and body weight reduction.
Report a problemFND-2813880308
09HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, treatment satisfaction increased significantly in both the primary care and specialist cohorts on liraglutide.
In plain wordsIn adults with type 2 diabetes on liraglutide, treatment satisfaction rose in both primary care and specialist patients.
Peptide
Liraglutide
Outcome
IncreasePatient treatment satisfaction
Study
n: not reported in source
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Patient treatment satisfaction was also significantly increased in both cohorts.
2 context sentences(design, population, supporting numbers)
Summary · context
EVIDENCE is a prospective, observational study of 3152 adults with T2D recently starting or about to start liraglutide treatment in France.
Summary · context
We followed patients in the PCP and specialist settings for 2 years to evaluate the effectiveness of liraglutide in glycemic control and body weight reduction.
Report a problemFND-2813880309
10HumanObservational studySafety outcome
In adults with type 2 diabetes on liraglutide, reported gastrointestinal adverse events were less frequent in primary care patients (4.5%) than in specialist patients (16.1%).
In plain wordsIn adults with type 2 diabetes on liraglutide, gut side effects were reported less in primary care (4.5%) than in specialist care (16.1%).
Peptide
Liraglutide
Outcome
Not applicableGastrointestinal adverse events
Study
n: not reported in source
Comparator
Specialist-treated patients
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Measurements
Gastrointestinal adverse events
4.5%
PCP-treated
Gastrointestinal adverse events
16.1%
specialist-treated
Source sentences
Summary
Reported gastrointestinal adverse events were less frequent among PCP-treated patients compared with specialist-treated patients (4.5% vs. 16.1%).
2 context sentences(design, population, supporting numbers)
Summary · context
EVIDENCE is a prospective, observational study of 3152 adults with T2D recently starting or about to start liraglutide treatment in France.
Summary · context
We followed patients in the PCP and specialist settings for 2 years to evaluate the effectiveness of liraglutide in glycemic control and body weight reduction.
Report a problemFND-2813880310

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT01226966

Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 3,152Sept 2010 to Nov 2013

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 13 Feb 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.